NASDAQ:CBMG Cellular Biomedicine Group (CBMG) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free CBMG Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$17.67▼$19.7552-Week Range N/AVolume8,375 shsAverage Volume129,776 shsMarket Capitalization$384.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Cellular Biomedicine Group alerts: Email Address Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. About Cellular Biomedicine Group Stock (NASDAQ:CBMG)Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer and stem cell therapies for degenerative diseases in Greater China. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), T-cells with genetically modified, tumor antigen-specific T-cell receptors, and next generation neoantigen-reactive bio-markers based tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases The company's CAR-T products include CD20 for use in anti-tumor activities; CD22, a surface maker highly expressed in B cell malignancies in hairy cell leukemia; and B-cell maturation antigen therapies for treating refractory multiple myeloma in patients. It also develops NKG2D CAR therapies for use in NK cell signaling; alpha fetoprotein TCR-T therapies for treating hepatocellular carcinoma; tumor infiltrating lymphocyte therapies for treating immunogenic cancers; and knee osteoarthritis therapies, including AlloJoin therapy, which is in a Phase II clinical trial, as well as Re-Join that has completed the Phase IIb clinical trial. In addition, it engages in biopharmaceutical businesses, including research and development, technical support, technical service, and technology transfer activities in biomedical technology field; manufacturing non-food, pharmaceutical polypeptides, and medical devices; and the wholesale of cosmetics, sanitary products, and biological agents. The company has a collaboration agreement with Novartis Pharma AG to manufacture and supply their CAR-T cell therapy Kymriah in China. Cellular Biomedicine Group, Inc. was incorporated in 2001 and is headquartered in New York, New York.Read More Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. CBMG Stock News HeadlinesApril 30, 2024 | seekingalpha.comIntra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A BuyApril 25, 2024 | finance.yahoo.comThe 500 Largest Cellular IoT Projects Worldwide - 7th EditionMay 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 22, 2024 | markets.businessinsider.comBuy Rating on Intra-Cellular Therapies as Caplyta Shows Promise in Major Depressive Disorder MarketApril 22, 2024 | benzinga.comThe Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 ExpertsApril 19, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Thermo Fisher (TMO), Intra-Cellular Therapies (ITCI)April 17, 2024 | msn.comIntra-Cellular Therapies (ITCI) Price Target Increased by 7.08% to 91.50April 17, 2024 | msn.comIntra-Cellular Therapies (ITCI) Price Target Increased by 7.08% to 91.50May 5, 2024 | Stansberry Research (Ad)Gold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).April 17, 2024 | msn.comIntra-Cellular Launches 23% To Record High, Breaking Out After Depression Drug Scores BigApril 16, 2024 | msn.comDrugmaker Intra-Cellular Soars as Depression Trial SucceedsApril 11, 2024 | msn.comNew Consumer Cellular Store Opens In SheltonApril 10, 2024 | finanznachrichten.deAmerican Society for Transplantation and Cellular Therapy: ASTCT Supports the FDA's Approval of Earlier Use of CAR T-Cell Therapy for Multiple MyelomaApril 10, 2024 | finance.yahoo.comGlobal Cellular IoT Market Size To Worth USD 45.64 Billion By 2033 | CAGR Of 22.21%April 5, 2024 | markets.businessinsider.comIntra-Cellular Therapies Buy Rating: High Confidence in Caplyta’s Success for MDD TreatmentApril 3, 2024 | finance.yahoo.comCavli Wireless Gears Up to Introduce the 5G RedCap CQM220 Cellular IoT Module Alongside the Flagship CQS290 Android Module at Embedded World 2024March 29, 2024 | tmcnet.comCellular IoT and Low-power Wide-area Network (LPWAN) Modules Adapts to 5G and Non-Terrestrial Innovations, 2023 Research Study with Forecasts to 2026March 28, 2024 | msn.comWho Stars In The Consumer Cellular Commercial?March 26, 2024 | tmcnet.comCavli Wireless All Set to Introduce the 5G RedCap CQM220 Cellular IoT Module at Embedded World 2024March 21, 2024 | markets.businessinsider.comIntra-Cellular Promotes Michael To PresidentMarch 13, 2024 | msn.comIlluminating Cellular Dynamics Advancements in Visualizing Lipid Membrane Order with Solvatochromic ProbesMarch 11, 2024 | seekingalpha.comIntra-Cellular Therapies Is On FireMarch 6, 2024 | benzinga.comHHLR ADVISORS, LTD.'s Net WorthMarch 1, 2024 | finance.yahoo.comMillicom International Cellular S.A. (NASDAQ:TIGO) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?February 26, 2024 | msn.comMillicom International Cellular S.A. Q4 2023 Earnings PreviewFebruary 26, 2024 | markets.businessinsider.comIntra-Cellular Therapies: Sustained Growth and Buy Opportunity Amid Caplyta’s ProgressFebruary 24, 2024 | uk.news.yahoo.comAT&T and Other Providers Hit by Widespread Cellular OutagesSee More Headlines Receive CBMG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellular Biomedicine Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2020Today5/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBMG CUSIPN/A CIK1378624 Webwww.cellbiomedgroup.com Phone347-905-5663FaxN/AEmployees217Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-144.80% Return on Assets-61.68% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$340,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / BookN/AMiscellaneous Outstanding Shares19,478,000Free FloatN/AMarket Cap$384.69 million OptionableOptionable Beta1.35 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Bizuo Liu (Age 56)CEO, CFO & Exec. Director Comp: $541.33kDr. Yihong Yao (Age 53)Chief Scientific Officer Comp: $364.98kMr. Andrew K. Chan (Age 63)Chief Legal Officer (Gen. Counsel), Sr. VP of Corp. Devel. & Sec. Comp: $475.08kMr. Derrick C. LiHead of Strategy & Investor RelationsMs. Sarah KellyDirector of Corp. CommunicationsDr. Li ZhangChief Production OfficerProf. Zhong Chen KouChief Scientist of ImmunologyDr. Xia Meng Ph.D.BS, Head of Early Diagnosis & InterventionMr. Michael HumphriesHead of Devel. & StrategyMore ExecutivesKey CompetitorsiTeos TherapeuticsNASDAQ:ITOSAdaptive BiotechnologiesNASDAQ:ADPTHarpoon TherapeuticsNASDAQ:HARPReplimune GroupNASDAQ:REPLTScan TherapeuticsNASDAQ:TCRXView All Competitors CBMG Stock Analysis - Frequently Asked Questions How were Cellular Biomedicine Group's earnings last quarter? Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) released its quarterly earnings data on Monday, November, 9th. The biotechnology company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.25. The biotechnology company had revenue of $0.03 million for the quarter. What other stocks do shareholders of Cellular Biomedicine Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include CRISPR Therapeutics (CRSP), Aduro Biotech (ADRO), Amarin (AMRN), Anavex Life Sciences (AVXL), Adaptimmune Therapeutics (ADAP), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN), AT&T (T) and Iovance Biotherapeutics (IOVA). This page (NASDAQ:CBMG) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceDems have chosen Biden replacement?Paradigm PressUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellular Biomedicine Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.